Difference between revisions of "Bacitracin"

(Pharmacology: added excretion)
(References)
Line 40: Line 40:
  
 
==References==
 
==References==
 +
*BACiiM (bacitracin) [prescribing information], Horseheads, NY: X-Gen Pharmaceuticals Inc; June 2008.
 +
*Bacitracin (prescribing information). New York, NY: Pharmacia & Upjohn; September 2015.
 +
*Chia JK, Nakata MM, Park SS, et al, “Use of Bacitracin Therapy for Infection Due to Vancomycin-Resistant Enterococcus faecium,” Clin Infect Dis, 1995, 21(6):1520.  [PubMed 8749657]
 +
*Cohen SH, Gerding DN, Johnson S, et al, “Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for healthcare Epidemiology of American (SHEA) and the Infectious Diseases Society of America (IDSA), Infect Control Hosp Epidemiol, 2010, 31(5):431-55. [PubMed 20307191]
 +
*Damm S. Intraoperative anaphylaxis associated with bacitracin irrigation. Am J Health-Syst Pharm. 2011;68(4):323-327. [PubMed 21289327]
 +
*Dudley MN, McLaughlin JC, Carrington G, et al, “Oral Bacitracin vs Vancomycin Therapy for Clostridium difficile-Induced Diarrhea. A Randomized Double-Blind Trial,” Arch Intern Med, 1986, 146(6):1101-4.
 +
*Elsner P, Pevny I, Burg G. Anaphylaxis induced by topically applied bacitracin. Am J Contact Dermat.1990;1:162-164.
 +
 
<references/>
 
<references/>
 
[[Category:Pharmacology]]
 
[[Category:Pharmacology]]

Revision as of 13:11, 10 June 2019

Administration

  • Type: Topical antibiotic
  • Dosage Forms: ointment
  • Dosage strengths: 500 unit/g
  • Routes of Administration: topical, ophthalmic, IM
  • Common Trade Names: BACiiM, Baciguent, Bacitracin Ophthalmic Ointment

Adult Dosing

  • Apply to wound 2-5 times per day

Pediatric Dosing

  • Apply to wound 2-5 times per day
  • Staph pneumonia/empyema known to be susceptible to bacitracin: 900-1000 units/kg/day IM in 2 to 3 divided doses

Special Populations

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

  • Renal toxicity (IM only)

Common

  • Contact dermatitis

Pharmacology

  • Half-life:
  • Metabolism:
  • Excretion: Urine 10-40%

Mechanism of Action

  • Interferes with cell wall peptidoglycan activity
  • Active against staph

Comments

See Also

References

  • BACiiM (bacitracin) [prescribing information], Horseheads, NY: X-Gen Pharmaceuticals Inc; June 2008.
  • Bacitracin (prescribing information). New York, NY: Pharmacia & Upjohn; September 2015.
  • Chia JK, Nakata MM, Park SS, et al, “Use of Bacitracin Therapy for Infection Due to Vancomycin-Resistant Enterococcus faecium,” Clin Infect Dis, 1995, 21(6):1520. [PubMed 8749657]
  • Cohen SH, Gerding DN, Johnson S, et al, “Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for healthcare Epidemiology of American (SHEA) and the Infectious Diseases Society of America (IDSA), Infect Control Hosp Epidemiol, 2010, 31(5):431-55. [PubMed 20307191]
  • Damm S. Intraoperative anaphylaxis associated with bacitracin irrigation. Am J Health-Syst Pharm. 2011;68(4):323-327. [PubMed 21289327]
  • Dudley MN, McLaughlin JC, Carrington G, et al, “Oral Bacitracin vs Vancomycin Therapy for Clostridium difficile-Induced Diarrhea. A Randomized Double-Blind Trial,” Arch Intern Med, 1986, 146(6):1101-4.
  • Elsner P, Pevny I, Burg G. Anaphylaxis induced by topically applied bacitracin. Am J Contact Dermat.1990;1:162-164.